Bapat Vinayak, Buellesfeld Lutz, Peterson Mark D, Hancock Jane, Reineke David, Buller Chris, Carrel Thierry, Praz Fabien, Rajani Ronal, Fam Neil, Kim Han, Redwood Simon, Young Christopher, Munns Christopher, Windecker Stephan, Thomas Martyn
Department of Cardiothoracic Surgery and Cardiology, St. Thomas' Hospital, London, United Kingdom.
EuroIntervention. 2014 Sep;10 Suppl U:U120-8. doi: 10.4244/EIJV10SUA18.
Transcatheter aortic valve implantation (TAVI) has demonstrated the feasibility of treating valvular heart disease with transcatheter therapy. On the back of this success, various transcatheter concepts are being evaluated to treat other valvular disease, especially mitral regurgitation (MR). The concepts currently approved to treat MR replicate surgical mitral valve repair. However, most of them cannot eliminate MR completely. Similar to TAVI, a transcatheter mitral valve implantation may provide a valuable alternative. The FORTIS transcatheter mitral valve (Edwards Lifesciences, Irvine, CA, USA) is a self-expanding device implanted via a transapical approach. We describe our experience and early results in the first five patients treated on compassionate grounds. We also describe the details of the device, selection criteria and technical details of implantation.
经导管主动脉瓣植入术（TAVI）已证明经导管治疗瓣膜性心脏病的可行性。在此成功的基础上，正在评估各种经导管概念以治疗其他瓣膜疾病，尤其是二尖瓣反流（MR）。目前批准用于治疗MR的概念复制了外科二尖瓣修复术。然而，其中大多数无法完全消除MR。与TAVI类似，经导管二尖瓣植入术可能提供一种有价值的替代方案。FORTIS经导管二尖瓣（美国加利福尼亚州欧文市爱德华兹生命科学公司）是一种通过经心尖途径植入的自膨胀装置。我们描述了我们对首批五名基于同情理由接受治疗的患者的经验和早期结果。我们还描述了该装置的细节、选择标准和植入的技术细节。
